Dose-dependent effects of a selective phosphodiesterase-5-inhibitor on endothelial dysfunction induced by peroxynitrite in rat aorta

European Journal of Pharmacology

Volumn 615, Issue 1-3, 2009, Pages 155-162

  Korkmaz, Sevil ^a   Radovits, Tamás ^a,b   Barnucz, Eniko ^a   Neugebauer, Philipp ^a   Arif, Rawa ^a   Hirschberg, Kristóf ^a,b   Loganathan, Sivakkanan ^a   Seidel, Beatrice ^a   Karck, Matthias ^a   Szabó, Gábor ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Cyclic GMP; DNA injury; Endothelial dysfunction; Nitro oxidative stress; Peroxynitrite; Phosphodiesterase 5 inhibition

Indexed keywords

3 NITROTYROSINE; CYCLIC GMP; NITRIC OXIDE; PEROXYNITRITE; VARDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; AORTA; AORTA WALL; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTICLE; CONTROLLED STUDY; DNA STRAND BREAKAGE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; LOW DRUG DOSE; MALE; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

ACETYLCHOLINE; ANIMALS; AORTA, THORACIC; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; NITROPRUSSIDE; OXIDATIVE STRESS; PEROXYNITROUS ACID; PHOSPHODIESTERASE 5 INHIBITORS; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SULFONES; TRIAZINES; VASODILATION; VASODILATOR AGENTS;

EID: 67449141645     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.05.020     Document Type: Article

References (42)

1. Abou-Seif M.A., and Youssef A.A. Oxidative stress and male IGF-1, gonadotropin and related hormones in diabetic patients. Clin. Chem. Lab. Med. 39 (2001) 618-623
2. Antonova G.N., Snead C.M., Antonov A.S., Dimitropoulou C., Venema R.C., and Catravas J.D. Nitric oxide preconditioning regulates endothelial monolayer integrity via the heat shock protein 90-soluble guanylate cyclase pathway. Am. J. Physiol. Heart Circ. Physiol. 292 (2007) H893-903
3. Cai H., and Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 87 (2000) 840-844
4. Celik I., Surucu O., Dietz C., Heymach J.V., Force J., Hoschele I., Becker C.M., Folkman J., and Kisker O. Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res. 65 (2005) 11044-11050
5. Crow J.P., and Beckman J.S. The role of peroxynitrite in nitric oxide-mediated toxicity. Curr. Top. Microbiol. Immunol. 196 (1995) 57-73
6. Cuzzocrea S., Mazzon E., Dugo L., Di Paola R., Caputi A.P., and Salvemini D. Superoxide: a key player in hypertension. Faseb J. 18 (2004) 94-101
7. Das A., Ockaili R., Salloum F., and Kukreja R.C. Protein kinase C plays an essential role in sildenafil-induced cardioprotection in rabbits. Am. J. Physiol. Heart Circ. Physiol. 286 (2004) H1455-1460
8. Ehsan A., Sommer F., Schmidt A., Klotz T., Koslowski J., Niggemann S., Jacobs G., Engelmann U., Addicks K., and Bloch W. Nitric oxide pathways in human bladder carcinoma. The distribution of nitric oxide synthases, soluble guanylyl cyclase, cyclic guanosine monophosphate, and nitrotyrosine. Cancer 95 (2002) 2293-2301
9. Forstermann U., and Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 113 (2006) 1708-1714
10. Galie N., Ghofrani H.A., Torbicki A., Barst R.J., Rubin L.J., Badesch D., Fleming T., Parpia T., Burgess G., Branzi A., Grimminger F., Kurzyna M., and Simonneau G. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 353 (2005) 2148-2157
11. Hess A., Bloch W., Su J., Stennert E., Addicks K., and Michel O. Localisation of the nitric oxide (NO)/cGMP-pathway in the vestibular system of guinea pigs. Neurosci. Lett. 251 (1998) 185-188
12. Hirschberg K., Radovits T., Loganathan S., Entz L., Beller C.J., Gross M.L., Sandner P., Karck M., and Szabó G. Selective phosphodiesterase-5 inhibition reduces neointimal hyperplasia in rat carotid arteries after surgical endarterectomy. J. Thoracic Cardiovasc. Surg. 137 (2009) 1508-1514
13. Ischiropoulos H., and Beckman J.S. Oxidative stress and nitration in neurodegeneration: cause, effect, or association?. J. Clin. Invest. 111 (2003) 163-169
14. Kukreja R.C., Salloum F., Das A., Ockaili R., Yin C., Bremer Y.A., Fisher P.W., Wittkamp M., Hawkins J., Chou E., Kukreja A.K., Wang X., Marwaha V.R., and Xi L. Pharmacological preconditioning with sildenafil: basic mechanisms and clinical implications. Vascul. Pharmacol. 42 (2005) 219-232
15. Li J., Li W., Su J., Liu W., Altura B.T., and Altura B.M. Peroxynitrite induces apoptosis in rat aortic smooth muscle cells: possible relation to vascular diseases. Exp. Biol. Med. (Maywood) 229 (2004) 264-269
16. Li J., Li W., Altura B.T., and Altura B.M. Peroxynitrite-induced relaxation in isolated rat aortic rings and mechanisms of action. Toxicol. Appl. Pharmacol. 209 (2005) 269-276
17. Liaudet L., Soriano F.G., Szabo E., Virag L., Mabley J.G., Salzman A.L., and Szabo C. Protection against hemorrhagic shock in mice genetically deficient in poly(ADP-ribose)polymerase. Proc. Natl. Acad. Sci. USA. 97 (2000) 10203-10208
18. Loganathan S., Radovits T., Hirschberg K., Korkmaz S., Barnucz E., Karck M., and Szabo G. Effects of selective phosphodiesterase-5-inhibition on myocardial contractility and reperfusion injury after heart transplantation. Transplantation 86 (2008) 1414-1418
19. Moncada S., Rees D.D., Schulz R., and Palmer R.M. Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc. Natl. Acad. Sci. USA. 88 (1991) 2166-2170
20. Munzel T., Genth-Zotz S., and Hink U. Targeting heme-oxidized soluble guanylate cyclase: solution for all cardiorenal problems in heart failure?. Hypertension 49 (2007) 974-976
21. Ogita H., and Liao J. Endothelial function and oxidative stress. Endothelium 11 (2004) 123-132
22. Pacher P., and Szabo C. Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme. Antioxid. Redox Signal. 7 (2005) 1568-1580
23. Pasquet J.P., Zou M.H., and Ullrich V. Peroxynitrite inhibition of nitric oxide synthases. Biochimie 78 (1996) 785-791
24. Radi R., Beckman J.S., Bush K.M., and Freeman B.A. Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch. Biochem. Biophys. 288 (1991) 481-487
25. Radovits T., Lin L.N., Zotkina J., Gero D., Szabo C., Karck M., and Szabo G. Poly(ADP-ribose) polymerase inhibition improves endothelial dysfunction induced by reactive oxidant hydrogen peroxide in vitro. Eur. J. Pharmacol. 564 (2007) 158-166
26. Radovits T., Zotkina J., Lin L.N., Bomicke T., Arif R., Gero D., Horvath E.M., Karck M., Szabo C., and Szabo G. Poly(ADP-ribose) polymerase inhibition improves endothelial dysfunction induced by hypochlorite. Exp. Biol. Med. (Maywood) 232 (2007) 1204-1212
27. Radovits T., Bomicke T., Kokeny G., Arif R., Loganathan S., Kecsan K., Korkmaz S., Barnucz E., Sandner P., Karck M., and Szabo G. The phosphodiesterase-5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus. Br. J. Pharmacol. 156 (2009) 909-919
28. Redon J., Oliva M.R., Tormos C., Giner V., Chaves J., Iradi A., and Saez G.T. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 41 (2003) 1096-1101
29. Reffelmann T., and Kloner R.A. Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation 108 (2003) 239-244
30. Salehi A., Vieira E., and Gylfe E. Paradoxical stimulation of glucagon secretion by high glucose concentrations. Diabetes 55 (2006) 2318-2323
31. Salloum F., Yin C., Xi L., and Kukreja R.C. Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ. Res. 92 (2003) 595-597
32. Salloum F.N., Ockaili R.A., Wittkamp M., Marwaha V.R., and Kukreja R.C. Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial K(ATP) channels in rabbits. J. Mol. Cell. Cardiol. 40 (2006) 405-411
33. Salvemini D., Doyle T.M., and Cuzzocrea S. Superoxide, peroxynitrite and oxidative/nitrative stress in inflammation. Biochem. Soc. Trans. 34 (2006) 965-970
34. Shabsigh R. Therapy of ED: PDE-5 inhibitors. Endocrine 23 (2004) 135-141
35. Szabo C. DNA strand breakage and activation of poly-ADP ribosyltransferase: a cytotoxic pathway triggered by peroxynitrite. Free Radic. Biol. Med. 21 (1996) 855-869
36. Szabo C. The pathophysiological role of peroxynitrite in shock, inflammation, and ischemia-reperfusion injury. Shock (Augusta, Ga.) 6 (1996) 79-88
37. Szabo C., and Salzman A.L. Endogenous peroxynitrite is involved in the inhibition of mitochondrial respiration in immuno-stimulated J774.2 macrophages. Biochem. Biophys. Res. Commun. 209 (1995) 739-743
38. Szabo C., Cuzzocrea S., Zingarelli B., O Connor M., and Salzman A.L. Endothelial dysfunction in a rat model of endotoxic shock. Importance of the activation of poly (ADP-ribose) synthetase by peroxynitrite. J. Clin. Invest. 100 (1997) 723-735
39. Turko I.V., and Murad F. Protein nitration in cardiovascular diseases. Pharmacol. Rev. 54 (2002) 619-634
40. van der Loo B., Labugger R., Skepper J.N., Bachschmid M., Kilo J., Powell J.M., Palacios-Callender M., Erusalimsky J.D., Quaschning T., Malinski T., Gygi D., Ullrich V., and Luscher T.F. Enhanced peroxynitrite formation is associated with vascular aging. J. Exp. Med. 192 (2000) 1731-1744
41. Van der Vliet A., Smith D., O Neill C.A., Kaur H., Darley-Usmar V., Cross C.E., and Halliwell B. Interactions of peroxynitrite with human plasma and its constituents: oxidative damage and antioxidant depletion. Biochem. J. 303 Pt 1 (1994) 295-301
42. Virag L., Szabo E., Gergely P., and Szabo C. Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention. Toxicol. Lett. 140-141 (2003) 113-124